Rachel M Lee1, Yuan Liu2,3, Adriana C Gamboa1, Mohammad Y Zaidi1, David A Kooby1, Mihir M Shah1, Kenneth Cardona1, Maria C Russell1, Shishir K Maithel1. 1. Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia. 2. Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, Georgia. 3. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND AND OBJECTIVES: Race/ethnicity and socioeconomic factors are associated with worse cancer outcomes. Our aim was to determine the association of these factors with receipt of surgery and multimodality therapy for cholangiocarcinoma. METHODS: Patients with cholangiocarcincoma in the National Cancer Database were identified. Racial/ethnic groups were defined as non-Hispanic White, non-Hispanic Black, Asian, and Hispanic. Socioeconomic factors were insurance status, income, and education. RESULTS: Of 12 095 patients with non-metastatic cholangiocarcinoma, 42% received surgery. Black race was associated with decreased odds of receiving surgery (odds ratio [OR]: 0.66l; P < .001) compared to White patients. Socioeconomic factors accounted for 21% of this disparity. Accounting for socioeconomic and clinicopathologic variables, Black race (OR: 0.73; P < .001), uninsured status (OR: 0.43; P < .001), and Medicaid insurance (OR: 0.63; P < .001) were all associated with decreased receipt of surgery. Of 4808 patients who received surgery, 47% received multimodality therapy. There were no racial/ethnic or socioeconomic differences in receipt of multimodality therapy once patients accessed surgical care. Similar results were seen in patients with advanced disease who received chemotherapy as primary treatment. CONCLUSION: Racial/ethnic and socioeconomic disparities exist in treatment for cholangiocarcinoma, however only for primary treatment. In patients who received surgery or chemotherapy, there were no disparities in receipt of multimodality therapy. This emphasizes the need to improve initial access to health care for minority and socioeconomical disadvantaged patients.
BACKGROUND AND OBJECTIVES: Race/ethnicity and socioeconomic factors are associated with worse cancer outcomes. Our aim was to determine the association of these factors with receipt of surgery and multimodality therapy for cholangiocarcinoma. METHODS:Patients with cholangiocarcincoma in the National Cancer Database were identified. Racial/ethnic groups were defined as non-Hispanic White, non-Hispanic Black, Asian, and Hispanic. Socioeconomic factors were insurance status, income, and education. RESULTS: Of 12 095 patients with non-metastatic cholangiocarcinoma, 42% received surgery. Black race was associated with decreased odds of receiving surgery (odds ratio [OR]: 0.66l; P < .001) compared to White patients. Socioeconomic factors accounted for 21% of this disparity. Accounting for socioeconomic and clinicopathologic variables, Black race (OR: 0.73; P < .001), uninsured status (OR: 0.43; P < .001), and Medicaid insurance (OR: 0.63; P < .001) were all associated with decreased receipt of surgery. Of 4808 patients who received surgery, 47% received multimodality therapy. There were no racial/ethnic or socioeconomic differences in receipt of multimodality therapy once patients accessed surgical care. Similar results were seen in patients with advanced disease who received chemotherapy as primary treatment. CONCLUSION: Racial/ethnic and socioeconomic disparities exist in treatment for cholangiocarcinoma, however only for primary treatment. In patients who received surgery or chemotherapy, there were no disparities in receipt of multimodality therapy. This emphasizes the need to improve initial access to health care for minority and socioeconomical disadvantaged patients.
Authors: Anasooya Abraham; Waddah B Al-Refaie; Helen M Parsons; Vikas Dudeja; Selwyn M Vickers; Elizabeth B Habermann Journal: Ann Surg Oncol Date: 2013-04-12 Impact factor: 5.344
Authors: Caroline Rieser; Heather Phelos; Amer Zureikat; James Pingpank; Melanie Ongchin; Andrew Lee; Joshua Brown; M Haroon Choudry; Richard S Hoehn Journal: Ann Surg Oncol Date: 2022-05-31 Impact factor: 4.339
Authors: Caroline J Rieser; Richard S Hoehn; Mazen Zenati; Lauren B Hall; Eliza Kang; Amer H Zureikat; Andrew Lee; Melanie Ongchin; Matthew P Holtzman; James F Pingpank; David L Bartlett; M Haroon A Choudry Journal: Ann Surg Oncol Date: 2021-03-09 Impact factor: 5.344
Authors: Lauren F Huang; Augustine Hong; Gino Cioffi; Asrar Alahmadi; Tin-Yun Tang; Lee M Ocuin; Nirav Patil; David L Bajor; Joel N Saltzman; Amr Mohamed; Eva Selfridge; Monica Webb Hooper; Jill Barnholtz-Sloan; Richard T Lee Journal: Front Oncol Date: 2022-02-22 Impact factor: 5.738